Back to Journals » OncoTargets and Therapy » Volume 11

RETRACTED ARTICLE: lncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcinoma

Authors Chen L , Liu J, Tang T, Zhang Y, Liu M, Xu L, Zhang J

Received 2 March 2018

Accepted for publication 2 July 2018

Published 9 November 2018 Volume 2018:11 Pages 7955—7965

DOI https://doi.org/10.2147/OTT.S167065

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jianmin Xu



This paper has been retracted.

Chen L, Liu J, Tang T, et al. Onco Targets Ther. 2018;11:7955–7965.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.

Since publication, concerns have been raised about the integrity of the data in the article. When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Creative Commons License © 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.